The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BRCT.F | +123.49% | N/A | N/A | +22% |
| S&P | +17.35% | +108.64% | +15.84% | +72% |
BioArctic AB engages in the research and development of modifying treatments and diagnostics for neurodegenerative diseases. Its research areas are Alzheimer’s disease and Parkinson’s disease where there are large unmet medical needs. The company was founded by Lars Gunnar Lannfelt and Pär Lars Gellerfors in 2003 and is headquartered in Stockholm, Sweden.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $40.59M | 770.5% |
| Gross Profit | $38.47M | 813.1% |
| Gross Margin | 94.77% | 4.4% |
| Market Cap | $1.71B | -8.3% |
| Market Cap / Employee | $14.39M | -26.0% |
| Employees | 119 | 24.0% |
| Net Income | $9.99M | 256.1% |
| EBITDA | -$7.01M | 0.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $99.49M | 115.2% |
| Accounts Receivable | $6.44M | 29019.6% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $3.63M | -17.9% |
| Short Term Debt | $1.51M | 23.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 57.43% | 65.7% |
| Return On Invested Capital | -4.60% | -5.7% |
| Current | YOY Change | |
|---|---|---|
| Operating Free Cash Flow | $118.86M | 1495.2% |
| Metric | Q4 2023 | Q1 2025 | Q2 2025 | YoY Change | |
|---|---|---|---|---|---|
| Price to Earnings | 107.32 | 19.23 | 16.44 | - | |
| Price to Book | 15.66 | 17.85 | 19.77 | 8.89 | -55.91% |
| Price to Sales | 86.89 | 65.78 | 11.42 | 9.32 | -86.40% |
| Price to Tangible Book Value | 15.66 | 17.85 | 17.67 | 8.89 | -55.91% |
| Enterprise Value to EBITDA | -208.78 | - | |||
| Return on Equity | -22.6% | -18.1% | 59.2% | 66.9% | -803.08% |
| Total Debt | $5.56M | $4.91M | $5.08M | $5.14M | -8.82% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
